Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

Hepatology

Volumn 24, Issue 3, 1996, Pages 711-713

  Ling, Roger ^a   Mutimer, David ^b   Ahmed, Monz ^b   Boxall, Elizabeth H ^c   Elias, Elwyn ^b   Dusheiko, Geoffrey M ^a   Harrison, Tim J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; METHIONINE; VALINE; VIRUS DNA; VIRUS ENZYME;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL;

EID: 0029815110     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008781347     Document Type: Article

References (13)

1. Muller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJ. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection, european concerted action on viral hepatitis. J Hepatol 1994;21:1140-1143.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
3. Schalm SW, Deman RA, Heijtink RA, Niesters HGM. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995;22:52-56.
4. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1984;12:387-395.
5. Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983;305:827-829.
6. Larder BA, Kemp SD, Purifoy DJ. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A 1989;86:4803-4807.
7. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 a resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.
8. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993;90:5653-5656.
9. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351-357.
10. Stirk HJ, Thornton JM, Howard CR. A topological model for hepatitis B surface antigen. Intervirology 1992;33:148-158.
11. Okamoto H, Imai M, Miyakawa Y, Mayumi M. Site-directed mutagenesis of hepatitis B surface antigen sequence at codon 160 from arginine to lysine for conversion of subtypic determinant from r to w. Biochem Biophys Res Commun 1987;148:500-504.
12. Norder H, Hammas B, Lee SD, Bile K, Courouce AM, Mushahwar IK, Magnius LO. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 1993;74:1341-1348.
13. Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983;11:1747-1757.